News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Sotrovimab benefits select hospitalized COVID-19 patients
23 Jan 2026
byAudrey Abella
In the RECOVERY* trial, the neutralizing monoclonal antibody (mAb) sotrovimab reduces mortality in hospitalized patients with COVID-19 pneumonia with a high baseline serum SARS-CoV-2 antigen concentration. However, this was not the case in the overall population.
23 Jan 2026

First phase III results show PFS benefit with pirtobrutinib vs BR in treatment-naïve CLL/SLL
22 Jan 2026
byNatalia Reoutova
Single-agent pirtobrutinib significantly improved progression-free survival (PFS) vs bendamustine plus rituximab (BR) for patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), according to the first results from the phase III BRUIN CLL-313 trial.
22 Jan 2026






